Literature DB >> 30945443

Malignant melanoma with areas of rhabdomyosarcomatous differentiation arising in a giant congenital nevus with RAF1 gene fusion.

Aline Baltres1, Aicha Salhi2, Aurelie Houlier1,3, Daniel Pissaloux1,3, Franck Tirode3, Véronique Haddad1, Marie Karanian1,3, Salim Ysmail-Dahlouk4, Fatma Boukendakdji5, Djazia Dahlouk5, Fateh Allaoua6, Marzak Metref6, Assya Djeridane7, Sylvie Fraitag8, Arnaud de la Fouchardière1,3.   

Abstract

A girl, born with a posterior  lumbosacral giant congenital nevus, developed a central nodule that expanded over a period of 14 months into a 10-cm pedunculated mass. Histological analysis of the mass revealed melanoma of myxoid, small round-cell type with areas of  rhabdomyosarcomatous  transformation confirmed by immunohistochemistry. RNA sequencing identified an in-frame SASS6(e14)-RAF1(e8) fusion in both components and the nevus. A RAF1 FISH break-apart test found a balanced rearrangement pattern in the nevus and an unbalanced pattern in the malignant areas. Wild-type status of NRAS and BRAF was confirmed by NGS techniques. The array-CGH profile displayed copy number alterations commonly found in rhabdomyosarcomas. Despite intensive treatment, widespread metastatic evolution of the melanomatous component was observed.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  RAF1 fusion; congenital melanoma; giant congenital nevus; rhabdomyosarcomatous differentiation; small-cell melanoma

Mesh:

Substances:

Year:  2019        PMID: 30945443     DOI: 10.1111/pcmr.12785

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  2 in total

1.  Domains and outcomes of the core outcome set of congenital melanocytic naevi for clinical practice and research (the OCOMEN project): part 2.

Authors:  A C Fledderus; S G M A Pasmans; A Wolkerstorfer; W Oei; H C Etchevers; M S van Kessel; C M A M van der Horst; P I Spuls
Journal:  Br J Dermatol       Date:  2021-07-14       Impact factor: 11.113

2.  Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles.

Authors:  Erik A Williams; Nikunj Shah; Meagan Montesion; Radwa Sharaf; Dean C Pavlick; Ethan S Sokol; Brian M Alexander; Jeff M Venstrom; Julia A Elvin; Jeffrey S Ross; Julie Y Tse; Mark C Mochel
Journal:  Mod Pathol       Date:  2020-03-02       Impact factor: 7.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.